360
A. Zakharov and A. Lagunin
ation of possible interaction between three drugs (HIV reverse transcriptase inhibitors—efavirenz, emtricitabine, and tenofovir disoproxil) using in the treatment of
HIV, which are included into the medicinal preparation Atripla [79], at a threshold
of Pa > 0.5, is represented at the Fig. 11.4.
Figure 11.4 shows that in addition to correctly predicted antiviral effect, the
known side effects given from Drugs.com (http://www.drugs.com/sfx/atripla-sideeffects.html): hepatotoxic, nephrotoxic and emetic were also predicted by PASS/
PharmaExpert as possible additive/synergistic side effects. None of additive/synergistic/antagonistic effects of the test compounds by reaction with drug metabolism
enzyme or transporter protein was predicted. The presence of such interactions on
the website Drugs.com information is also not shown. The known interactions of
the compounds with HIV reverse transcriptase (a known target of the studied drugs)
and RNA-dependent DNA polymerase (the name of the general class of enzymes
including HIV reverse transcriptase) were also predicted.
The another example of the interaction analysis between compounds from Saint
John’s wort by PharmaExpert was described by Lagunin and co-authors [80].
Fig. 11.4 The results of PharmaExpert analysis of drug-drug interaction between the three drugs
from Atripla. Comments are marked in italics
A. Zakharov and A. Lagunin
ation of possible interaction between three drugs (HIV reverse transcriptase inhibitors—efavirenz, emtricitabine, and tenofovir disoproxil) using in the treatment of
HIV, which are included into the medicinal preparation Atripla [79], at a threshold
of Pa > 0.5, is represented at the Fig. 11.4.
Figure 11.4 shows that in addition to correctly predicted antiviral effect, the
known side effects given from Drugs.com (http://www.drugs.com/sfx/atripla-sideeffects.html): hepatotoxic, nephrotoxic and emetic were also predicted by PASS/
PharmaExpert as possible additive/synergistic side effects. None of additive/synergistic/antagonistic effects of the test compounds by reaction with drug metabolism
enzyme or transporter protein was predicted. The presence of such interactions on
the website Drugs.com information is also not shown. The known interactions of
the compounds with HIV reverse transcriptase (a known target of the studied drugs)
and RNA-dependent DNA polymerase (the name of the general class of enzymes
including HIV reverse transcriptase) were also predicted.
The another example of the interaction analysis between compounds from Saint
John’s wort by PharmaExpert was described by Lagunin and co-authors [80].
Fig. 11.4 The results of PharmaExpert analysis of drug-drug interaction between the three drugs
from Atripla. Comments are marked in italics